ATE487482T1 - Superoxid-dismutase-mimika zur behandlungvon augenstörungen und erkrankungen - Google Patents

Superoxid-dismutase-mimika zur behandlungvon augenstörungen und erkrankungen

Info

Publication number
ATE487482T1
ATE487482T1 AT03790363T AT03790363T ATE487482T1 AT E487482 T1 ATE487482 T1 AT E487482T1 AT 03790363 T AT03790363 T AT 03790363T AT 03790363 T AT03790363 T AT 03790363T AT E487482 T1 ATE487482 T1 AT E487482T1
Authority
AT
Austria
Prior art keywords
treatment
diseases
superoxide dismutase
eye disorders
dismutase mimics
Prior art date
Application number
AT03790363T
Other languages
English (en)
Inventor
Peter Klimko
Robert Collier
Mark Hellberg
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Application granted granted Critical
Publication of ATE487482T1 publication Critical patent/ATE487482T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
AT03790363T 2002-12-06 2003-12-05 Superoxid-dismutase-mimika zur behandlungvon augenstörungen und erkrankungen ATE487482T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43141402P 2002-12-06 2002-12-06
PCT/US2003/038677 WO2004052283A2 (en) 2002-12-06 2003-12-05 Superoxide dismutase mimics for the treatment of ocular disorders and diseases

Publications (1)

Publication Number Publication Date
ATE487482T1 true ATE487482T1 (de) 2010-11-15

Family

ID=32507724

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03790363T ATE487482T1 (de) 2002-12-06 2003-12-05 Superoxid-dismutase-mimika zur behandlungvon augenstörungen und erkrankungen

Country Status (12)

Country Link
US (3) US7754706B2 (de)
EP (1) EP1567166B1 (de)
JP (1) JP2006510668A (de)
CN (1) CN1717238A (de)
AT (1) ATE487482T1 (de)
AU (1) AU2003293416B2 (de)
BR (1) BR0317021A (de)
CA (1) CA2505333A1 (de)
DE (1) DE60334926D1 (de)
ES (1) ES2353382T3 (de)
MX (1) MXPA05005937A (de)
WO (1) WO2004052283A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05005937A (es) * 2002-12-06 2005-08-18 Alcon Inc Imitaciones de superoxido de dismutasa para el tratamiento de trastornos y enfermedades oculares.
AU2005287343A1 (en) * 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
EP2433640B1 (de) 2010-09-24 2020-01-15 OmniVision GmbH Zusammensetzung mit SOD, Lutein und Zeaxanthin
US10683316B2 (en) 2011-11-10 2020-06-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic catalase/superoxide dismutase mimetics and methods for treating viral infections
WO2021224679A1 (en) * 2020-05-05 2021-11-11 Genofocus, Inc. Compositions comprising enzymes and probiotics, and methods for preventing or treating macular degeneration

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3773926D1 (de) 1987-07-22 1991-11-21 Farvalsa Ag Feuchtigkeitsstabile feste valproinsaeure-zubereitung und verfahren zu ihrer herstellung.
US5075116A (en) * 1989-04-20 1991-12-24 Lahaye Laboratories, Inc. Composition and method for treatment of macular degeneration
US5696109A (en) * 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US6127356A (en) * 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5994339A (en) * 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US6214817B1 (en) * 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6180620B1 (en) * 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
DE69813898T2 (de) * 1997-11-03 2004-03-11 Duke University Substituierte porphyrinen
AU5251999A (en) 1998-08-04 2000-02-28 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
GB9817845D0 (en) * 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
WO2000023568A2 (en) 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
ES2240101T3 (es) 1999-05-27 2005-10-16 Monsanto Company Biomateriales modificados con mimeticos de superoxido dismutasa.
MXPA05005937A (es) 2002-12-06 2005-08-18 Alcon Inc Imitaciones de superoxido de dismutasa para el tratamiento de trastornos y enfermedades oculares.

Also Published As

Publication number Publication date
EP1567166A4 (de) 2009-06-17
AU2003293416B2 (en) 2009-03-26
AU2003293416A1 (en) 2004-06-30
JP2006510668A (ja) 2006-03-30
MXPA05005937A (es) 2005-08-18
US20060035880A1 (en) 2006-02-16
DE60334926D1 (de) 2010-12-23
US20100179117A1 (en) 2010-07-15
CN1717238A (zh) 2006-01-04
US7754706B2 (en) 2010-07-13
EP1567166B1 (de) 2010-11-10
US20040116402A1 (en) 2004-06-17
US8067405B2 (en) 2011-11-29
ES2353382T3 (es) 2011-03-01
CA2505333A1 (en) 2004-06-24
WO2004052283A2 (en) 2004-06-24
WO2004052283A3 (en) 2004-09-16
EP1567166A2 (de) 2005-08-31
BR0317021A (pt) 2005-10-25

Similar Documents

Publication Publication Date Title
BR0317026A (pt) Mìmicos de superóxido dismutase para o tratamento de distúrbios e doenças oculares
CY1108983T1 (el) Μιμητικα της υπεροξειδικης δισμουτασης για την αγωγη οφθαλμικων διαταραχων και νοσων
ATE326475T1 (de) Cyclische salen metall verbindungen als einfänger von sauerstoffradikalen und verwendbar als antioxidantien bei der behandlung und vorbeugung von krankheiten
ATE539701T1 (de) Zusammengesetzte schlinge zur behandlung von inkontinenz
WO2005097119A3 (en) Pten inhibitors
MY140767A (en) Compounds, methods and compositions
WO2006069078A3 (en) Treatment of anal incontinence
DE602006009834D1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
WO2005049000A3 (en) Treatment of phenylketonurias with bh4
EP2359832A3 (de) Therapeutische mittel zum targeting des ncca-atp-kanals und verwendungsverfahren dafür
GEP20094781B (en) Sulfonamide derivatives for the treatment of diseases
CY1106409T1 (el) Παραγωγα κινολινης
MXPA04000124A (es) Composicion farmaceutica para la terapia de cistitis intersticial.
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
DE60334926D1 (de) Superoxid-dismutase-mimika zur behandlungvon augenstörungen und erkrankungen
MXPA06012143A (es) Arilsulfonamidas y usos relacionados con las mismas.
DE60224667D1 (de) Perylenequinonen zur anwendung als sonosensitizer
DE60138385D1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
DE60008151D1 (de) 5-ht2 agonisten als mittel zur kontrolle des augeninnendrucks und zur behandlung von glaukom
ATE448779T1 (de) Methode zur behandlung trockener augen und uveitis
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
ATE253936T1 (de) Glutathion-reduktase zur behandlung und prophylaxe von aids
BRPI0417549A (pt) miméticos de superóxido dismutase para o tratamento de lesão de nervo óptico e retinal
WO2007040568A3 (en) Production and use of human butyrylcholinesterase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties